Abstract
Immune checkpoint inhibitors increased overall survival for patients with advanced and metastatic melanoma, but long-term treatment responses are still limited to few patients with tumor specific effector T-cells at the tumor sites as predictors for treatment success. Thus, new treatment strategies are required. In preclinical models we could recently show, that targeted activation of melanoma- associated mast cells (MC) with lipopolysaccharide (LPS) induces an effective anti-melanoma immune response in a Toll-like receptor (TLR) 4-dependent manner.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
